Skip to main content
NCBI home page
eLife logoLink to eLife
. 2023 Mar 28;12:e84151. doi: 10.7554/eLife.84151

Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors

Marc Kschonsak 1,†, Christine C Jao 1,†, Christopher P Arthur 1, Alexis L Rohou 1, Philippe Bergeron 2, Daniel F Ortwine 2, Steven J McKerrall 2, David H Hackos 3, Lunbin Deng 3, Jun Chen 4, Tianbo Li 4, Peter S Dragovich 2, Matthew Volgraf 2, Matthew R Wright 5, Jian Payandeh 1,✉, Claudio Ciferri 1,✉, John C Tellis 2,✉
Editors: Jon T Sack6, Richard W Aldrich7
PMCID: PMC10112885  PMID: 36975198

Abstract

The voltage-gated sodium (NaV) channel NaV1.7 has been identified as a potential novel analgesic target due to its involvement in human pain syndromes. However, clinically available NaV channel-blocking drugs are not selective among the nine NaV channel subtypes, NaV1.1–NaV1.9. Moreover, the two currently known classes of NaV1.7 subtype-selective inhibitors (aryl- and acylsulfonamides) have undesirable characteristics that may limit their development. To this point understanding of the structure–activity relationships of the acylsulfonamide class of NaV1.7 inhibitors, exemplified by the clinical development candidate GDC-0310, has been based solely on a single co-crystal structure of an arylsulfonamide inhibitor bound to voltage-sensing domain 4 (VSD4). To advance inhibitor design targeting the NaV1.7 channel, we pursued high-resolution ligand-bound NaV1.7-VSD4 structures using cryogenic electron microscopy (cryo-EM). Here, we report that GDC-0310 engages the NaV1.7-VSD4 through an unexpected binding mode orthogonal to the arylsulfonamide inhibitor class binding pose, which identifies a previously unknown ligand binding site in NaV channels. This finding enabled the design of a novel hybrid inhibitor series that bridges the aryl- and acylsulfonamide binding pockets and allows for the generation of molecules with substantially differentiated structures and properties. Overall, our study highlights the power of cryo-EM methods to pursue challenging drug targets using iterative and high-resolution structure-guided inhibitor design. This work also underscores an important role of the membrane bilayer in the optimization of selective NaV channel modulators targeting VSD4.

Research organism: Human

Introduction

Voltage-gated sodium (NaV) channels initiate and propagate action potentials in excitable cells and play important roles in health and disease (Catterall et al., 2005; Ahern et al., 2016). The NaV1.7 channel is expressed predominantly in the peripheral nervous system, and genetic studies have identified compelling loss-of-function and gain-of-function phenotypes in human pain syndromes, prompting significant efforts to develop NaV1.7-selective inhibitors as potential novel analgesic drugs (Dib-Hajj et al., 2013; Payandeh and Hackos, 2018; McKerrall and Sutherlin, 2018). NaV channels contain 24-transmembrane segments linked in four homologous domains (DI-DIV), where four peripheral voltage-sensor domains (VSD1-4) surround a central ion-conducting pore module that houses the ion selectivity filter and key ligand and toxin binding sites. Traditionally, all clinically available NaV channel inhibitors lack significant molecular selectivity among the NaV1.1–1.9 subtypes owing to the high sequence conservation found at the ligand binding site within the central cavity of the ion-conducting pore module (McKerrall and Sutherlin, 2018; de Lera Ruiz and Kraus, 2015).

A breakthrough study in 2013 by McCormack and colleagues reported the discovery of an arylsulfonamide antagonist, PF-04856264, that bound to an unprecedented receptor site in VSD4 with demonstrated molecular selectivity for human NaV1.7 over other subtypes (McCormack et al., 2013). However, the related development candidate PF-05089771 did not meet clinical endpoints in human subjects with painful diabetic peripheral neuropathy, possibly due to poor target coverage and the intolerable doses required to achieve efficacy (Swain et al., 2017; McDonnell et al., 2018; Siebenga et al., 2020). Additionally, an alternate acylsulfonamide inhibitor that also targeted the VSD4 receptor site in NaV1.7, GDC-0276, was halted in phase I clinical trials due to safety concerns and potential off-target effects likely attributed to the high lipophilicity of the compound (Rothenberg et al., 2019; Safina et al., 2021). To date, selective NaV1.7 inhibitors with an improved therapeutic index relative to these clinical-stage compounds have not yet been identified, and this absence underscores the need to optimize such molecules using modern, structure-guided design approaches.

The inherent complexity and dynamic nature of human NaV channels have historically presented significant barriers to obtaining high-resolution experimental structural information, especially of inhibitor-bound complexes (Noreng et al., 2021). Using an engineered human VSD4 NaV1.7-NaVAb bacterial channel chimera and X-ray crystallography, the binding mode of the GX-936 arylsulfonamide inhibitor revealed that the anionic sulfonamide group engages the fourth arginine gating charge (R4) to trap VSD4 in an activated conformation, which in turn stabilizes a non-conductive, inactivated state of the channel (Ahuja et al., 2015). While determinants of subtype selectivity and structure–activity relationships (SAR) of the arylsulfonamide inhibitor class could be rationalized by the GX-936 co-crystal structure, additional ligand-bound structures of suitable resolution were not returned by the NaV1.7-NaVAb chimeric channel crystallography system. This shortcoming led molecular docking studies to presume that the acylsulfonamide inhibitors also bound VSD4 in an analogous manner, despite points of inexplicable SAR (Sun et al., 2019). The overall paucity of direct structural information has made the optimization of NaV1.7 inhibitors challenging, with many questions about the determinants of potency, selectivity, and the relationship between the acylsulfonamide and arylsulfonamide inhibitor classes remaining unanswered.

Over the last three decades, protein crystallography and structure-based drug design (SBDD) have become gold standards across the pharmaceutical industry for the identification of ligand binding pockets and the optimization of drug candidates for clinical development. While SBDD has proven successful for many important targets, including G protein-coupled receptors (GPCRs) (Congreve et al., 2014), its applicability to several membrane protein targets, such as NaV channels, has been limited due to the extreme difficulties with their iterative crystallization and structure determination (Noreng et al., 2021). Cryogenic electron microscopy (cryo-EM) has recently emerged as a transformative technique to determine the high-resolution structures of diverse protein targets and has proven particularly effective for membrane proteins that are recalcitrant to crystallization (Cheng, 2018). Despite this breakthrough, cryo-EM structure determination of membrane targets in complex with small or large molecule therapeutics frequently remains retrospective and is often enabled after the advancement of key molecules into the clinic (Balestrini et al., 2021; Rougé et al., 2020). Slow turnaround times and modest resolutions typically offered by cryo-EM have limited its application for real-time SBDD efforts. Here, we describe a system for the iterative determination of high-resolution NaV1.7-VSD4 small molecule co-structures via cryo-EM that has led to the development of a novel class of inhibitors. Critical to this advancement has been the establishment of a robust protocol for sample preparation and structure determination and the first structure of an acylsulfonamide bound to NaV1.7-VSD4, revealing a previously unknown inhibitor binding pocket between the S3 and S4 helices. Consequently, a novel hybrid inhibitor series bridging the aryl and acylsulfonamide pockets was designed and validated. Our work exemplifies the deployment of cryo-EM as a workhorse structural biology tool in an active medicinal chemistry campaign and thus represents an important milestone toward NaV channel drug discovery.

Results

Structure of the GNE-3565-VSD4 NaV1.7-NaVPas channel complex in lipid nanodiscs

Our approach to establish an iterative, high-resolution system to enable NaV1.7 SBDD was ultimately guided by three observations: our repeated failure to generate well-diffracting crystals of the NaV1.7-NaVAb bacterial channel chimera system (Ahuja et al., 2015), our difficulty of reproducibly expressing a suitable amount of full-length human NaV1.7 channel (Xu et al., 2019; Clairfeuille, 2019), and the very limited local resolution observed at VSD4 in all available human Nav1.7 cryo-EM structures (Shen et al., 2019; Huang et al., 2022). Thus, we sought to exploit an engineered human VSD4-NaV1.7-NaVPas cockroach channel chimeric construct that had been previously shown to complex with small molecule inhibitors and peptide toxins known to target VSD4 (Clairfeuille, 2019). The recovered protein yields following expression and purification (50 µg/L) allowed us to readily pursue reconstitution of the VSD4-NaV1.7-NaVPas channel into lipid nanodiscs (Figure 1, Figure 1—figure supplement 1). Small molecule inhibitors were added prior to sample vitrification, followed by cryo-EM data collection and processing procedures, which allowed us to routinely obtain 3D-reconstructions in the 2.2–3.0Å resolution range around the VSD4 inhibitor binding site (Figure 1).

Figure 1. Structure of VSD4-NaV1.7-NaVPas.

(A) Schematic of the VSD4-NaV1.7-NaVPas channel. The portions humanized to the NaV1.7 sequence are shown in green. N-terminal domain (NTD) and CTD are indicated. (B) Side view of the single-particle cryogenic electron microscopy (cryo-EM) reconstruction of VSD4-NaV1.7-NaVPas channel. (C, D) Cartoon representations of the top and side views of VSD4-NaV1.7-NaVPas channel. Individual VSD domains are indicated. VSD4 is highlighted in green. (E) Localization of water molecules (in red) in the VSD4-NaV1.7-NaVPas channel structure. VSD4 is highlighted in green.

Figure 1.

Figure 1—figure supplement 1. Purification of VSD4-NaV1.7-NaVPas channel.

Figure 1—figure supplement 1.

(A) VSD4-NaV1.7-NaVPas channel protein expression and purification scheme. (B) Example size-exclusion chromatogram and SDS-PAGE of nanodisc-reconstituted VSD4-NaV1.7-NaVPas channel sample.
Figure 1—figure supplement 1—source data 1. Source data of VSD4-NaV1.7-NaVPas purification.
Open in a new tab

The VSD4-NaV1.7-NaVPas chimera displays the expected domain-swapped arrangement with numerous densities assigned as phospholipids bound to the channel, confirming the maintenance of a native membrane-like environment (Figure 1). As seen in previous NaVPas structures (Clairfeuille, 2019; Shen et al., 2017; Shen et al., 2018), the ion-conducting pore module of the VSD4-NaV1.7-NaVPas chimeric channel is closed, consistent with a nonconductive or inactivated state. The quality and resolution of our structure allowed us to assign 111 water molecules for the highest resolution structure (Figure 1E, Video 1). The visualization of many well-resolved water molecules bound within the VSDs and coordinated within the ion selectivity filter provides new insights into the interactions that might occur during gating charge transfer and ion conduction, respectively.

Video 1. Movie illustrating the quality of VSD4-NaV1.7-NaVPas channel bound to GNE-1305.

Download video file (53.1MB, mp4)
Open in a new tab

Several water molecules can be observed.

Although we were able to determine the crystal structure of VSD4-NaVAb bound to the arylsulfonamide inhibitor GX-936 (Ahuja et al., 2015), no well-diffracting crystals were obtained for any other arylsulfonamide compounds despite years of continued effort. Arylsulfonamide GNE-3565 is representative of an advanced series of arylsulfonamide class NaV1.7 inhibitors that demonstrates channel blockage at subnanomolar concentrations with mixed subtype selectivity (Figure 2A). We complexed GNE-3565 with the VSD4 NaV1.7-NaVPas channel-nanodisc system and employed cryo-EM to assess its overall binding pose (Figure 2B and C). The 2.9 Å resolution cryo-EM map revealed that the S1-S2 and S3-S4 helices from VSD4 form a clamshell-like structure that closes over GNE-3565 (Figure 2D and E, Figure 2—figure supplement 1, Figure 2—figure supplement 2, Supplementary file 1A), similar to the binding pose reported for GX-936 (Ahuja et al., 2015). Specifically, the ionized arylsulfonamide group of GNE-3565 (measured pKa = 5.8) bisects VSD4 to salt-bridge directly to R4 on the S4 helix, while the central phenyl ring extends perpendicular between the S2 and S3 helices to directly contact established subtype-selectivity determinants Tyr1537 and Trp1538 on the S2 helix (Figure 2A–D). As for GX-936, the GNE-3565, arylsulfonamide VSD4 receptor binding site can be divided into three regions: an anion-binding pocket, a selectivity pocket, and a lipid-exposed pocket (Figure 2D). The root-mean-square deviation (RMSD) between the GNE-3565-VSD4 and the GX-936-VSD4 structures (Ahuja et al., 2015) is 0.667 (714–714 atoms) (Figure 2—figure supplement 2), supporting long-held assumptions by medicinal chemistry teams that all structurally related arylsulfonamides should be expected to complex to VSD4 through similar determinants (Swain et al., 2017; Weiss et al., 2017; Graceffa et al., 2017; McKerrall et al., 2019; Roecker et al., 2021; Focken et al., 2016; Wu et al., 2017).

Figure 2. Structure of GNE-3565 bound to VSD4-NaV1.7-NaVPas.

(A) Chemical structure of arylsulfonamide GNE-3565. (B, C) Top and side views of VSD4-NaV1.7-NaVPas channel bound to GNE-3565. VSD4 is highlighted in green, GNE-3565 in magenta. (D) Extracellular view of VSD4-NaV1.7-NaVPas arylsulfonamide receptor site is shown with select side chains rendered as sticks. (E) The cryogenic electron microscopy (cryo-EM) map surrounding the ligand GNE-3565 is shown in mesh representation. (F) View toward the membrane highlighting key interactions with the GNE-3565 anionic group. (G) View from the membrane highlighting key interactions with the GNE-3565 central phenyl ring.

Figure 2.

Figure 2—figure supplement 1. Cryo-EM processing workflow of GNE-3565 and GNE-9296.

Figure 2—figure supplement 1.

(A) Data collection and processing workflow for VSD4-NaV1.7-NaVPas channel bound to GNE-3565. (B) Heat map representation of the distribution of assigned particle orientations. (C) Fourier shell corellation (FSC) between two half datasets yields a global resolution estimate of approximately 2.9 Å resolution from the refinement using an overall mask of the VSD4-NaV1.7-NaVPas channel bound to GNE-3565. (D) Local resolution of maps. (E) Data collection and processing workflow for VSD4-NaV1.7-NaVPas channel bound to GNE-9296 (compound 2). (F) Heat map representation of the distribution of assigned particle orientations. (G) FSC between two half datasets yields a global resolution estimate of approximately 3.1 Å resolution from the refinement using an overall mask of the VSD4-NaV1.7-NaVPas channel bound to GNE-9296 (compound 2). (H) Local resolution of maps.
Figure 2—figure supplement 2. Comparison of VSD4-NaV1.7 bound to the arylsulfonamides GNE-3565 and GX-936 (PDB:5EK0).

Figure 2—figure supplement 2.

Open in a new tab

Structure of the acylsulfonamide GDC-0310 in complex with the VSD4 NaV1.7-NaVPas channel

To investigate the binding pose of a representative NaV1.7-selective acylsulfonamide, GDC-0310 (Figure 3A) was complexed with the VSD4 NaV1.7-NaVPas channel in nanodiscs and a cryo-EM structure was determined to 2.5 Å resolution (Figure 3B–D, Figure 3—figure supplement 1, Supplementary file 1A). Remarkably, the binding mode of GDC-0310 revealed an unexpected and previously unknown pocket that formed between the S3 and S4 helices (Figure 3B–E). While the aryl and acyl moieties of GDC-0310 and GNE-3565 bind in the same region, the remainder of the acyl receptor site is orthogonal to the corresponding binding domain reported for the aryl class (Figure 3B–D). In detail, the anionic acylsulfonamide of GDC-0310 participates in salt-bridge bonding interactions with R4 and R3 through the carbonyl and sulfonamide oxygen atoms, respectively (Figure 3F). Moreover, the aryl ring of the GDC-0310 splits the S3 and S4 helices to occupy a lipophilic pocket, displacing the S3 helix laterally by ~3 Å relative to the GNE-3565-VSD4 structure (Figure 3G). Our cryo-EM structures serve to highlight a dynamic environment in VSD4 where the S1-S4 helixes can be differentially separated by the binding of distinct small molecule inhibitors (Figure 2D and Figure 3D).

Figure 3. Structure of GDC-0310 bound to VSD4-NaV1.7-NaVPas.

(A) Chemical structure of acylsulfonamide GDC-0310. (B) Top and side views of VSD4-NaV1.7-NaVPas channel bound to GDC-0310. VSD4 is highlighted in green, GDC-0310 in magenta. (D) Extracellular view of VSD4-NaV1.7-NaVPas acylsulfonamide receptor site is shown with select side chains rendered as sticks. (E) The cryogenic electron microscopy (cryo-EM) map surrounding the ligand GDC-0310 is shown in mesh representation. (F) View toward the membrane highlighting key interactions with the GDC-0310 warhead. (G) View from the membrane highlighting van der Waals interactions with the GDC-0310 cyclopropyl substituent. The alpha-methylbenzylamine tail region sits almost entirely within the lipid bilayer.

Figure 3.

Figure 3—figure supplement 1. CyroEM processing workflow for GNE-1305 and GDC-0310.

Figure 3—figure supplement 1.

(A) Example cryogenic electron microscopy (cryo-EM) micrograph image of the VSD4-NaV1.7-NaVPas channel. (B) Representative 2D-class averages of selected particles. (C) Data collection and processing workflow for VSD4-NaV1.7-NaVPas channel bound to compound 4. (D) Heat map representation of the distribution of assigned particle orientations. (E) FSC between two half datasets yields a global resolution estimate of approximately 2.2 Å resolution from the refinement using an overall mask of the VSD4-NaV1.7-NaVPas channel bound to GNE-1305 (compound 4) (F) Local resolution of maps. (G) Data collection and processing workflow for VSD4-NaV1.7-NaVPas channel bound to GDC-0310. (H) Heat map representation of the distribution of assigned particle orientations. (I) FSC between two half datasets yields a global resolution estimate of approximately 2.5 Å resolution from the refinement using an overall mask of the VSD4-NaV1.7-NaVPas channel bound to GDC-0310. (J) Local resolution of maps.
Open in a new tab

It is notable that the cyclopropyl substituent of GDC-0310 makes effective van der Waals interactions with I1574 and I1588 from S3 and I1601 and I1604 on S4 (Figure 3G), while the alpha-methylbenzylamine ‘tail’ region sits almost entirely within the lipid bilayer (Figure 3A and C), where density for this portion of the inhibitor is only poorly resolved (Figure 3E). Considering the relative depth of the­ GDC-0310 binding site in relation to the membrane-water interface (~8 Å), our structure suggests a membrane access pathway for acylsulfonamides to the VSD4 receptor site, which has important implications for understanding the pharmacology, SAR, and potential development liabilities of the inhibitor series (Payandeh and Volgraf, 2021). Notably, this structure also reveals that the Tyr1537 side chain on S2 exists in a down rotamer conformation and does not contact GDC-0310 directly, which provides the first direct structural rationale for why the selectivity profiles between the acyl and arylsulfonamide classes differ substantially (Figure 3D, vide infra; Bankar et al., 2018).

Structure-based rational design of hybrid NaV1.7 inhibitors

Upon inspection of the superimposed GNE-3565-aryl and GDC-0310-acyl structures, we could immediately envision a novel class of hybrid inhibitors that would simultaneously occupy both the aryl- and acylsulfonamide binding pockets (Figure 4A and B). Such an enlarged hybrid binding pocket would offer unique opportunities to gain potency directly from ligand–protein interactions, which might enable removal of the hydrophobic lipid-facing tail groups seen in all previous generations of VSD4-targeting NaV channel inhibitors. These groups have typically been critical for maintaining potency, but use of the plasma membrane to drive membrane-bound target occupancy is largely nonspecific, and potentially introduces off-target liabilities that can contribute to toxicity. However, it was unclear whether this hybrid conformation of the VSD4 domain could accommodate the described inhibitors and/or whether it was accessible during any stage of NaV1.7 channel gating. We therefore set out to demonstrate a proof of concept that appropriately designed small molecules could induce this hypothesized binding site while inhibiting channel function with meaningful potency.

Figure 4. Structure-based design of potent hybrid inhibitors of NaV1.7.

(A) Illustration of hybrid molecule design approach. (B) Arylsulfonamide, acylsulfonamide, and hybrid molecule poses. (C) Hybridization strategy and molecule optimization. Highlighted are molecule 2 (GNE-9296) and molecule 4 (GNE-1305). (D) Extracellular view of VSD4-NaV1.7-NaVPas bound to the hybrid molecule 2 (GNE-9296). (E) View toward the membrane highlighting key interactions with the anionic group. (F) View from the membrane highlighting the lack of a stacking interaction between Y1537 and the phenyl ring. (G) Extracellular view of VSD4-NaV1.7-NaVPas bound to the hybrid molecule 4 (GNE-1305). (H) View toward the membrane highlighting key interactions with the anionic group. (I) View from the membrane highlighting the p-stacking interaction between Y1537 and the phenyl ring.

Figure 4.

Figure 4—figure supplement 1. Biophysical and pharmacological characterization of human Nav1.7 channel by using Syncropatch384.

Figure 4—figure supplement 1.

(A) Activation and inactivation curves of Nav1.7. Activation V1/2 = –25.2 mV (95% CI: –25.8 to –24.6 mV, n = 36). Inactivation V1/2 = –66.2 mV (95% CI: –66.6 to –65.7 mV, n = 153). (B). Pharmacology protocol and representative current traces for tetracaine block. Cells were held at –50 mV, pulsed to –10 mV for 10 ms, followed by a 20 ms pulse at –150 mV and 10 ms pulse to –10 mV. Currents elicited at the second –10 mV pulse were used to derive inhibition at inactivated states. Current traces showed 100 nM tetracaine block of Nav1.7 during a 7.5 min time period (from black to gray trace). (C) Representative dose responses of key compounds on human Nav1.7 channel. For each compound, 2–3 repeats were run, along with tetracaine control. (D) Summary of inhibition potency on Nav1.7, Nav1.5, and Nav1.6. Please note tetracaine was included as control for all experiments.
Figure 4—figure supplement 2. Density maps of GNE-9296 and GNE-1305.

Figure 4—figure supplement 2.

(A) The cryogenic electron microscopy (cryo-EM) map surrounding the ligand GNE-9296 (compound 2) is shown in mesh representation. (B) The cryo-EM map surrounding the ligand GNE-1305 (compound 4) is shown in mesh representation.
Figure 4—figure supplement 3. Multiple sequence alignment of human VSD4 NaV1.

Figure 4—figure supplement 3.

1–1.9 sequences.
Open in a new tab

GDC-0310 was a relatively unattractive starting point for hybridization because of its high molecular weight (543 g/mol) and lipophilicity (cLogP = 5.2). Accordingly, re-evaluation of potency and physicochemical property data available for previously synthesized NaV1.7 inhibitors identified progenitor compound 1, which offers reasonable potency against NaV1.7 (IC50 = 25 nM, n = 8; Figure 4C, Figure 4—figure supplement 1) and reduced molecular weight (350 g/mol) and lipophilicity (cLogP = 2.7). Seeking to leverage existing knowledge of the arylsulfonamide binding pocket, GNE-9296 (compound 2) was synthesized in an attempt to directly graft on a significant portion of the GNE-3565 scaffold. Gratifyingly, this molecule retained substantial potency, affording channel blockade at an IC50 of 47 nM (n = 8).

A cryo-EM structure of GNE-9296 bound to the VSD4 NaV1.7-NaVPas channel confirmed that the molecule adopts the desired hybrid binding mode (Figure 4D, Figure 4—figure supplement 2A). Here, the anionic group of the novel hybrid compound binds in the same position as in the aryl and acyl poses, interacting closely with R4, as seen for the aryl-like binding (Figure 4E). The aryl- and acylsulfonamide-derived structural motifs of GNE-9296 occupy their expected positions in the pockets formed between S2/S3 and S3/S4, respectively. Notably, in this hybrid configuration, Y1537 adopts a similar arrangement as observed for the arylsulfonamides (Figure 4F).

Encouraged by this result, we hoped to draw on previously established knowledge of acylsulfonamide SAR to improve the potency of this compound. Established SAR within the acylsulfonamide series suggested that replacement of the chloro substituent on the benzamide fragment of the molecule with a cyclopropane would typically improve potency. This SAR proved translatable to the hybrid class molecules, resulting in inhibitor 3 (IC50 = 16nM, n = 12; Figure 4C, Figure 4—figure supplement 1, Figure 4—figure supplement 2A).

Further analysis of the cryo-EM structure of GNE-9296 revealed that the aryl ring in the S2/S3 binding pocket was shifted ~1 Å away from the VSD4 core compared to arylsulfonamides such as GNE-3565 (data not shown). The aryl ring in the S3/S4 pocket exhibited better overlap with the analogous substituents in the GDC-0310 structure. We hypothesized that the acylsulfonamide moiety of GNE-9296, which places the two aryl substituents 4.7 Å apart, might not be fully optimized for use in hybrid inhibitors. In comparison, an arylsulfonamide moiety would position these two groups at a distance of ~3.3 Å. On this basis, we designed N-benzothiazolyl sulfonamide GNE-1305 (compound 4), which demonstrated potent NaV1.7 inhibition (IC50 = 9nM, n = 8, Figure 4C, Figure 4—figure supplement 1, Figure 4—figure supplement 2B).

Our last hypothesis was again validated with a cryo-EM co-structure of GNE-1305 bound to the VSD4 NaV1.7-NaVPas channel (Figure 4G, Figure 4—figure supplement 2B). Here, we observed the typical face-on pi-stacking orientation of the S2/S3 substituent with Y1537 while maintaining efficient space filling in the S3/S4 pocket. Moreover, the efficient occupation of the non-membrane exposed regions of the binding pocket permitted the removal of the lipophilic tail of the molecule in 5, where a CF3 group replaces the cyclopentylmethyl substituent. Although this molecule shows reduced potency (IC50 = 74 nM, n = 8), lack of substantial small molecule contact with the lipid bilayer is an uncommon feature in all other known NaV1.7 VSD4 domain inhibitors. These molecules serve as a key proof of concept, highlighting the power of cryo-EM to yield new structural insights that can inspire the design of novel, structurally differentiated small molecule NaV channel inhibitors.

Discussion

Iterative structure-based design is among the most powerful techniques to facilitate the development of small molecule drug candidates. Although a variety of technologies are capable of providing information about small molecule ligand–protein interactions, SBDD has traditionally been synonymous with the use of X-ray crystallography, with other techniques failing to rival its high resolution and fast cycle times. Here, we have demonstrated that a robust cryo-EM structure pipeline is capable of quickly providing co-structures at resolutions suitable for use in an active medicinal chemistry optimization campaign. Moreover, we have highlighted the power of structural methods, and cryo-EM in particular, to provide new and important insights into inhibitor design through the discovery of a previously unknown binding mode for acylsulfonamide NaV1.7 inhibitors. We further note that our use of an engineered VSD4-NaV1.7-NaVPas chimeric channel construct was essential to produce sufficient yields of recombinant protein capable of routinely returning multiple cryo-EM samples per preparation. This system repeatedly delivered high-resolution depictions of the VSD4 inhibitor binding site and thus contrasts with prior accounts of VSD4 in cryo-EM structures of full-length human NaV1.7 channels (Shen et al., 2019; Huang et al., 2022) Importantly, high-quality cryo-EM maps of VSD4 in complex with ICA121431 have recently been reported from full-length human NaV1.3 channel protein (Li et al., 2022), indicating that SBDD efforts targeting a particular NaV channel subtype would likely benefit from exploring both engineered and native channel sample options at early project stages.

The co-structure of GDC-0310 was critical to contextualize historical differences between aryl- and acylsulfonamide NaV1.7 inhibitors, which include divergent SAR in the linker phenyl ring and tail regions, disparate NaV family selectivity patterns, and differences in on-rates and off-rates (Safina et al., 2021; Sun et al., 2019; Bankar et al., 2018; Luo et al., 2019; DiMauro et al., 2016; Focken et al., 2018). Previous efforts to model acylsulfonamide binding have attempted to dock molecules into the GX-936 co-structure and have proposed subtle changes in molecular register and/or pose to explain the non-translatable SAR (Sun et al., 2019; Kotla et al., 2019). Here, we demonstrate that the molecular features of aryl- and acylsulfonamide inhibitors diverge because they occupy distinct, but overlapping, pockets within the VSD4 domain.

The selectivity determinants of arylsulfonamide NaV1.7 inhibitors have been well studied. Mutation of key non-conserved residues proximal to the binding pocket observed in the GX-936 co-structure has been shown to alter NaV1.7 potency consistent with selectivity patterns observed for other NaV family members (Ahuja et al., 2015; Figure 4—figure supplement 3). Typically, arylsulfonamides have shown high levels of selectivity against NaV1.5, NaV1.1, and NaV1.4, but lower selectivity against NaV1.2 and NaV1.6. In comparison, several acylsulfonamides have been characterized with very high selectivity over NaV1.2 and NaV1.6 (Bankar et al., 2018). Interestingly, residues forming the contours of the acylsulfonamide binding pocket show high sequence homology across NaV isoforms, suggesting that selectivity for this class is likely an allosteric phenomenon. Nonetheless, the disparate binding pockets for these two inhibitor classes provide a clear rationale for their historically divergent patterns of selectivity.

Our structure of GDC-0310 provides a structural rationale for the relative slow dissociation kinetics of acylsulfonamide inhibitors compared to arylsulfonamides (Bankar et al., 2018). Specifically, the acylsulfonamide pocket is buried more deeply into the plasma membrane than the arylsulfonamide pocket, and may only be available through a membrane-access pathway that first involves partitioning of the molecule into the hydrophobic core of the membrane. In comparison, the arylsulfonamide pocket is more open to the outer membrane leaflet–aqueous interface, potentially offering access or egress directly from (or to) the solvent compartment. It is increasingly recognized that slow dissociation kinetics may be associated with membrane-access pathways for small molecules binding to transmembrane proteins (Payandeh and Volgraf, 2021; Mason et al., 1991; Coleman et al., 1996; Anderson et al., 1994; Masureel et al., 2018; Austin et al., 2003; Rhodes et al., 1992; Sykes et al., 2014; Dickson et al., 2016).

In addition to offering valuable information for retrospective analysis of historical NaV1.7 VSD4 domain inhibitors, the structure of GDC-0310 inspired the development of a class of structurally differentiated inhibitors that trap a novel conformation of VSD4. These hybrid molecules bridge both the S2/S3 and S3/S4 helical gaps, with the anionic moiety situated centrally, interacting with the arginine gating charge network within the core of the domain. We have demonstrated that potent hybrid inhibitors can be designed with fewer membrane-associated elements than prior generation NaV1.7 inhibitors, and anticipate that this will offer opportunities to develop molecules with improved lipophilic ligand efficiency and/or differentiated pharmacokinetic profiles. Hybrid inhibitors can also access selectivity determinants from both the S2/S3 and S3/S4 pockets simultaneously, offering a tantalizing opportunity to develop exquisite selectivity over other NaV isoforms. Although selectivity was not a key endpoint of our proof-of-concept studies described here, hybrid molecules 2–5 are selective for NaV1.7 over the cardiac channel NaV1.5. Further discussion of selectivity patterns in the hybrid series is included in Supplementary file 1B.

Beyond the scope of NaV channel inhibitors, our experiences may also offer lessons translatable to small molecule modulators of other transmembrane proteins. Specifically, it is noteworthy to observe that both aryl- and acylsulfonamide inhibitors have access to inducible pockets that are not observable in the parent small molecule co-structures. Designing small molecules to ‘push’ on a structural protein element is a common strategy in medicinal chemistry, but it is often challenging to predict when such efforts will afford new, well-defined binding pockets. As such, these designs are often met with failure and quickly abandoned. However, some scenarios exist in which an inducible pocket is more likely to be found. In these cases, medicinal chemists are more often emboldened to continue experimenting with designs that push into new areas of a protein binding pocket, even when met with initial failure. For example, type II kinase inhibitors can be rationally designed starting from a type I inhibitor structure by appending groups that push into the hydrophobic back pocket (Zhao et al., 2014). This pocket is not visible from the type I inhibitor structure, but knowledge of the protein dynamics associated with the DFG-in/DFG-out transition provides a rationale for exploring these designs. We speculate that transmembrane proteins, particularly intrinsically dynamic ones including ion channels, transporters, and GPCRs, may commonly present privileged structural motifs that are rich with opportunities for the discovery of novel druggable pockets.

In summary, we have developed a robust pipeline for high-resolution structural determination of small-molecules bound to NaV1.7-VSD4 suitable for use in iterative structure-based drug design campaigns. We also report the first co-structure of an acylsulfonamide inhibitor bound to the VSD4 domain of NaV1.7, revealing an unexpected and unique binding mode. This finding provides clear rationale for previously unexplainable divergence in the in vitro pharmacological behavior between inhibitor classes, and inspired the development of hybrid inhibitors that engages VSD4 in a novel conformation. Our findings highlight the power of cryo-EM as an enabling drug discovery technology and offer insights into ion channel structural dynamics that are potentially applicable to related targets and other target classes.

Materials and methods

Generation of VSD4-NaV1.7-NaVPas channel constructs

VSD4-NaV1.7-NaVPas chimeric constructs were used as described previously (Clairfeuille, 2019). In brief, optimized coding DNA for NaV1.7 VSD4-NaVPaS chimeras with N-terminal tandem StrepII and FLAG tag was cloned into a pRK vector with CMV promoter. HEK293 cells in suspension were cultured in SMM 293T-I medium under 5% CO2 at 37°C and transfected using PEI when the cell density reached 4 × 106 cells per mL. Transfected cells were harvested 48 hr after transfection. The Dc1a toxin coding DNA from Diguetia canities was cloned into a modified pAcGP67A vector downstream of the polyhedron promoter and an N-terminal 6x HIS tag. Recombinant baculovirus was generated using the Baculogold system (BD Biosciences) and Trichoplusia ni cells were infected for protein production. The supernatant was harvested 48 hr post-infection.

Protein expression and purification

In total, 150 g of cell pellet was resuspended in 500 mL of 25 mM HEPES pH 7.5, 200 mM NaCl, 1 ug/mL benzonase, 1 mM PMSF, and Roche protease inhibitor tablets. Cells were lysed by dounce homogenization. Proteins were solubilized by addition of 2% GDN (Avanti) with 0.3% cholesteryl hemisuccinate (Avanti) for 2 hr at 4°C. Cell debris was separated by ultracentrifugation at 40,000 rpm at 4°C. Affinity purification using anti-Flag resin was performed by batch binding for 1 hr at 4°C. The resin was washed with 5CV Purification Buffer (25 mM HEPES pH 7.5, 200 mM NaCl, 0.01% GDN). Another 5CV wash was performed using Purification Buffer supplemented with 5 mM ATP and 10 mM MgCl2. Proteins were eluted in 6CV Purification Buffer with 300 ug/mL Flag peptide. Proteins were subjected to another round of affinity purification using StrepTactin resin (IBA). Proteins were eluted and concentrated to ~5 mg/mL. For the compound 2 containing sample, instead of nanodisc reconstitution VSD4-NaV1.7-NaVPas was incubated overnight with Dc1a toxin at a 2:1 molar ration of toxin:VSD4-NaV1.7-NaVPas. The eluted sample was concentrated to 100 uL and separated on Superose 6 3.2/300.

For nanodisc reconstitution used for the samples containing GNE-3565, GDC-0310, and compound 4, a 200-molar excess of lipid mix (3POPC:1POPE:1POPG resuspended in 50 mM HEPES pH7.5, 100 mM NaCl, 5 mM MgCl2, 1% CHAPS) was added to detergent-solubilized protein and incubated on ice for 30 min. A four-molar excess of scaffold protein (MSP1E3D1, Sigma) was added to the protein-lipid mix and incubated on ice for another 30 min. To remove detergent, BioBeads (Bio-Rad) were added to 0.25 mg/mL and incubated overnight at 4°C. To remove the empty nanodiscs, the sample was subjected to a round of affinity purification using Strep-Tactin (IBA). The eluted sample was concentrated to 100 uL and separated on Superose 6 3.2/300. Peak fractions were combined and split into four samples. Then, 50 uM of the small molecule of interest was added to each sample and incubated at 22°C for 10 min. Samples were crosslinked with 0.05% glutaraldehyde (Electron Microscopy Sciences) then quenched with 1 M Tris pH 7.0. Samples at 2 mg/mL were used for grid freezing.

Cryo-EM sample preparation and data acquisition

Cryo-EM grids for the small molecule VSD4-NaV1.7-NaVPas chimeric complexes shown in this study were prepared as follows: for the GDC-0310 and compound 4 VSD4-NaV1.7-NaVPas complexes, holey carbon grids (Ultrafoil 25 nM Au R 0.6/1 300 mesh; Quantifoil) were incubated with a thiol reactive, self-assembling reaction mixture of 4 mM monothiolalkane(C11)PEG6-OH (11-mercaptoundecyl) hexaethyleneglycol (SPT-0011P6, SensoPath Technologies, Inc, Bozeman, MT). Grids were incubated with this self-assembled monolayer (SAM) solution for 24 hr and afterward rinsed with EtOH. 3 μL of the sample was applied to the grid and blotted with Vitrobot Mark IV (Thermo Fisher) using 3.5 s blotting time with 100% humidity and plunge-frozen in liquid ethane cooled by liquid nitrogen. The GNE-3565 VSD4-NaV1.7-NaVPas complex was, similarly as described above, applied to a holey carbon grid (Ultrafoil 25 nM Au R 1.2/1,3 300 mesh; Quantifoil) pretreated with SAM solution. The grid was blotted single-sided with a Leica EM GP (Leica) using 3 s blotting time with 100% humidity and plunge-frozen in liquid ethane cooled by liquid nitrogen. For compound 2 VSD4-NaV1.7-NaVPas-DC1a complex, holey carbon grids (Ultrafoil 25 nM Au R 2/2 200 mesh; Quantifoil) were glow-discharged for 10 s using the Solarus plasma cleaner (Gatan). 3 μL of the sample was applied to the grid and blotted with Vitrobot Mark IV (Thermo Fisher) using 2.5 s blotting time with 100% humidity and plunge-frozen in liquid ethane cooled by liquid nitrogen.

Movie stacks for compound 2 VSD4-NaV1.7-NaVPas-DC1a complex were collected using SerialEM (Mastronarde, 2005) on a Titan Krios operated at 300 keV with bioquantum energy filter equipped with a K2 Summit direct electron detector camera (Gatan). Images were recorded at ×165,000 magnification corresponding to 0.824 Å per pixel using a 20 eV energy slit. Each image stack contains 50 frames recorded every 0.2 s for an accumulated dose of ~50 e Å−2 and a total exposure time of 10 s. Images were recorded with a set defocus range of 0.5–1.5 μm.

Movie stacks for GNE-3565, GDC-0310, and compound 4 VSD4-NaV1.7-NaVPas complexes were collected using SerialEM on a Titan Krios G3i (Thermo Fisher Scientific, Waltham, MA) operated at 300 keV with bioquantum energy filter equipped with a K3 Summit direct electron detector camera (Gatan Inc, Pleasanton, CA). Images were recorded in EFTEM mode at ×105,000 magnification corresponding to 0.838 Å per pixel, using a 20 eV energy slit. Each image stack contains 60 frames recorded every 0.05 s for an accumulated dose of ~60 e Å−2 and a total exposure time of 3 s. Images were recorded with a set defocus range of 0.5–1.5 μm.

Cryo-EM data processing

Cryo-EM data were processed using a combination of the RELION (Scheres, 2012) and cisTEM (Grant et al., 2018) software packages, similarly as described previously (Kschonsak et al., 2022) and as illustrated in Figure 2—figure supplement 1 and Figure 3—figure supplement 1.

Movies were corrected for frame motion using the MotionCor2 (Zheng et al., 2017) implementation in RELION, and contrast-transfer function parameters were fit using the 30–4.5 Å band of the spectrum with CTFFIND-4 (Rohou and Grigorieff, 2015). CTF-fitted images were filtered on the basis of the detected fit resolution better than 6–10 Å. Particles were picked by template-matching with Gautomatch using a 30 Å low-pass filtered apo VSD4-NaV1.7-NaVPas reference structure. Particles were sorted during RELION 2D classification, and selected particles were imported into cisTEM for 3D refinements. 3D reconstructions were obtained after auto-refine and manual refinements with a mask around the channel (excluding the detergent micelle) and by applying low-pass filter outside the mask (filter resolution 20 Å) and a score threshold of 0.10–0.30, so that only the best-scoring 10–30% of particle images would be included in the 3D reconstruction at each cycle. The weight outside of the mask was set to 0.8. No data beyond 3.0 Å for compound 4, 3.4 Å for GDC-0310, 3.7 Å GNE-3565, and 4.0 Å for compound 2 were used in the refinements. Phenix ResolveCryoEM (Terwilliger et al., 2020) density modification was applied to each of the reconstructions to obtained the final map used for model building. Local resolution was determined in cisTEM using a reimplementation of the blocres algorithm.

Model building and structure analysis

The previously determined VSD4-NaV1.7-NaVPas model (PDB: 6NT3; Clairfeuille, 2019) was fit as a rigid body into the cryo-EM map. After manual adjustments, multiple rounds of real space refinement using the phenix.real_space_refinement tool (Afonine et al., 2018b) were used to correct structural differences between the initial model and the map. The small molecule coordinates were generated with eLBOW (Moriarty et al., 2009), placed and manually adjusted in Coot (Emsley et al., 2010), energy minimized with MOE (Chemical Computing Group ULC), and refined with real space refinements in Phenix (Afonine et al., 2018b). The model was validated using phenix.validation_cryoem (Afonine et al., 2018a) with built-in MolProbity scoring (Williams et al., 2018). Figures were made using PyMOL (The PyMOL Molecular Graphics System, v.2.07 Schrödinger, LLC), UCSF Chimera (Pettersen et al., 2004), and UCSF ChimeraX (Goddard et al., 2018).

Chemical synthesis

The synthesis of GNE-3565, GDC-0310, and compound 1 has been previously reported (Safina et al., 2021; Sun et al., 2019; Sutherlin, 2021). The synthesis and characterization of compounds 2–5 are described in the supporting information.

NaV1.7 biophysical and pharmacological characterization of Nav1.7 channel using Syncropatch electrophysiology

cDNA for NaV1.7 (NM_002977) were stably expressed in Chinese Hamster Ovary (CHO) cells. Sodium currents were measured in the whole-cell configuration using Syncropatch 384PE (NanIon Technologies, Germany). 1NPC–384 chips with custom medium resistance and single hole mode were used. Internal solution consisted of (in mM) 110 CsCl, 10 CsCl, 20 EGTA, and 10 HEPES (pH adjusted to 7.2); and external solution contains (in mM) 60 NMDG, 80 NaCl, 4 KCl, 1 MgCl2, 2 CaCl2, 2 D-glucose monohydrate, and 10 HEPES (pH adjusted to 7.4 with NaOH). To assess voltage-dependent activation of Nav1.7, currents were elicited by 20 ms test pulses (−80 to 20 mV in 5 mV increments) from a holding potential at –120 mV. To determine voltage-dependent inactivation, peak currents at 0 mV were obtained after 500 ms conditioning pre-pulses varying from –120–15 mV.

After system flushing, testing compounds were dissolved in external solution containing 0.1% Pluronic F-127. 10 µL cells were added to the chip from a cell hotel, and a negative pressure of −50 mBar was applied to form a seal. Following treatment with seal enhancer solution and wash-off with external solution, negative pressure of −250 mbar was applied for 1 s to achieve the whole-cell configuration, followed by three washing steps in external solution. 20 µL of compounds were added to 40 µL in each well (1:3 dilution of compounds), and after mixing, 20 µL was removed so the volume was retained at 40 uL. After approximately 13 min recording, 20 µL/well of 2 uM TTX was added to achieve full block.

For pharmacological characterization, a holding potential of –50 mV was applied during the whole experiment. A depolarizing step was applied to –10 mV for 10 ms, followed by a hyperpolarization step to –150 mV for 20 ms to allow channel recovery from inactivation. A second depolarizing step was applied from –150 mV to –10 mV for 10 ms, where currents were measured to derive blocking effects of compounds. Inhibition was determined based on 7.5 min of compound incubation.

For all recordings, currents were sampled at 10 kHz and filtered with Bessel filter. Seal resistance (Rseal) was calculated using built-in protocols; and series resistance was compensated at 80%. Several parameters were applied for quality control, including: cell catching (>10 MU), seal resistance (>500 MΩ), series resistances (<10 MΩ), and baseline current amplitude (>500 pA and <5 nA). Data were further examined by manual inspection.

Biophysical and pharmacological characterizations, including voltage-dependent activation, voltage-dependent inactivation, pharmacological protocol, a sample trace, IC50 values, and individual dose responses are shown in Figure 4—figure supplement 1.

Acknowledgements

We are grateful to BMR and RMG for construct generation and protein scale-up. We are thankful to Cameron Noland for help with the biochemistry of the VSD4-NaV1.7-NaVPas channel system. We thank Tommy Lai and Wenfeng Liu for chemistry support.

Funding Statement

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Contributor Information

Jian Payandeh, Email: jpayandeh@exelixis.com.

Claudio Ciferri, Email: ciferri.claudio@gene.com.

John C Tellis, Email: tellis.john@gene.com.

Jon T Sack, University of California, Davis, United States.

Richard W Aldrich, The University of Texas at Austin, United States.

Funding Information

This paper was supported by the following grant:

  • Genentech to Marc Kschonsak.

Additional information

Competing interests

are Genentech employees.

Author contributions

Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing.

Data curation, Formal analysis, Validation, Visualization, Methodology.

Formal analysis, Methodology.

Methodology.

Methodology.

Formal analysis.

Formal analysis.

Formal analysis.

Formal analysis.

Formal analysis.

Data curation, Formal analysis.

Conceptualization.

Formal analysis.

Conceptualization.

Conceptualization, Supervision, Investigation, Writing – original draft, Writing – review and editing.

Conceptualization, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing.

Conceptualization, Data curation, Formal analysis, Supervision, Investigation, Visualization, Writing – original draft, Writing – review and editing.

Additional files

Supplementary file 1. Experimental details for Cryo-EM, compound synthesis and characterization, and NaV subtype selectivity for selected NaV1.7 inhibitors.

(A) Cryogenic electron microscopy (cryo-EM) data collection, refinement and validation statistics. (B) NaV subtype selectivity for selected hybrid compounds.

elife-84151-supp1.docx (872.5KB, docx)
MDAR checklist

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files. The NaV1.7-NaVPas/GNE-3565 coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0R and EMDB entry ID EMD-28778, respectively. The NaV1.7-NaVPas/GDC-0310 coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0Q and EMDB entry ID EMD-28777, respectively. The NaV1.7-NaVPas bound to the hybrid molecule 2 (GNE-9296) coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0S and EMDB entry ID EMD-28779, respectively. The NaV1.7-NaVPas bound to the hybrid molecule 4 (GNE-1305) coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0P and EMDB entry ID EMD-28776, respectively.

The following datasets were generated:

Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Otwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeth J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the arylsulfonamide inhibitor GNE-3565. RCSB Protein Data Bank. 8F0R

Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Otwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the arylsulfonamide inhibitor GNE-3565. Electron Microscopy Data Bank. EMD-28778

Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Ortwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the acylsulfonamide inhibitor GDC-0310. RCSB Protein Data Bank. 8F0Q

Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Ortwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the acylsulfonamide inhibitor GDC-0310. Electron Microscopy Data Bank. EMD-28777

Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Ortwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the hybrid inhibitor GNE-9296. RCSB Protein Data Bank. 8F0S

Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Ortwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the hybrid inhibitor GNE-9296. Electron Microscopy Data Bank. EMD-28779

Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Ortwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the hybrid inhibitor GNE-1305. RCSB Protein Data Bank. 8F0P

Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Ortwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the hybrid inhibitor GNE-1305. Electron Microscopy Data Bank. EMD-28776

References

  1. Afonine PV, Klaholz BP, Moriarty NW, Poon BK, Sobolev OV, Terwilliger TC, Adams PD, Urzhumtsev A. New tools for the analysis and validation of cryo-EM maps and atomic models. Acta Crystallographica. Section D, Structural Biology. 2018a;74:814–840. doi: 10.1107/S2059798318009324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Afonine PV, Poon BK, Read RJ, Sobolev OV, Terwilliger TC, Urzhumtsev A, Adams PD. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallographica. Section D, Structural Biology. 2018b;74:531–544. doi: 10.1107/S2059798318006551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ahern CA, Payandeh J, Bosmans F, Chanda B. The hitchhiker’s guide to the voltage-gated sodium channel galaxy. The Journal of General Physiology. 2016;147:1–24. doi: 10.1085/jgp.201511492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ahuja S, Mukund S, Deng L, Khakh K, Chang E, Ho H, Shriver S, Young C, Lin S, Johnson JP, Jr, Wu P, Li J, Coons M, Tam C, Brillantes B, Sampang H, Mortara K, Bowman KK, Clark KR, Estevez A, Xie Z, Verschoof H, Grimwood M, Dehnhardt C, Andrez J-C, Focken T, Sutherlin DP, Safina BS, Starovasnik MA, Ortwine DF, Franke Y, Cohen CJ, Hackos DH, Koth CM, Payandeh J. Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist. Science. 2015;350:aac5464. doi: 10.1126/science.aac5464. [DOI] [PubMed] [Google Scholar]
  5. Anderson GP, Lindén A, Rabe KF. Why are long-acting beta-adrenoceptor agonists long-acting? The European Respiratory Journal. 1994;7:569–578. doi: 10.1183/09031936.94.07030569. [DOI] [PubMed] [Google Scholar]
  6. Austin RP, Barton P, Bonnert RV, Brown RC, Cage PA, Cheshire DR, Davis AM, Dougall IG, Ince F, Pairaudeau G, Young A. Qsar and the rational design of long-acting dual D2-receptor/beta 2-adrenoceptor agonists. Journal of Medicinal Chemistry. 2003;46:3210–3220. doi: 10.1021/jm020886c. [DOI] [PubMed] [Google Scholar]
  7. Balestrini A, Joseph V, Dourado M, Reese RM, Shields SD, Rougé L, Bravo DD, Chernov-Rogan T, Austin CD, Chen H, Wang L, Villemure E, Shore DGM, Verma VA, Hu B, Chen Y, Leong L, Bjornson C, Hötzel K, Gogineni A, Lee WP, Suto E, Wu X, Liu J, Zhang J, Gandham V, Wang J, Payandeh J, Ciferri C, Estevez A, Arthur CP, Kortmann J, Wong RL, Heredia JE, Doerr J, Jung M, Vander Heiden JA, Roose-Girma M, Tam L, Barck KH, Carano RAD, Ding HT, Brillantes B, Tam C, Yang X, Gao SS, Ly JQ, Liu L, Chen L, Liederer BM, Lin JH, Magnuson S, Chen J, Hackos DH, Elstrott J, Rohou A, Safina BS, Volgraf M, Bauer RN, Riol-Blanco L. A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment. The Journal of Experimental Medicine. 2021;218:e20201637. doi: 10.1084/jem.20201637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bankar G, Goodchild SJ, Howard S, Nelkenbrecher K, Waldbrook M, Dourado M, Shuart NG, Lin S, Young C, Xie Z, Khakh K, Chang E, Sojo LE, Lindgren A, Chowdhury S, Decker S, Grimwood M, Andrez J-C, Dehnhardt CM, Pang J, Chang JH, Safina BS, Sutherlin DP, Johnson JP, Jr, Hackos DH, Robinette CL, Cohen CJ. Selective Nav1.7 antagonists with long residence time show improved efficacy against inflammatory and neuropathic pain. Cell Reports. 2018;24:3133–3145. doi: 10.1016/j.celrep.2018.08.063. [DOI] [PubMed] [Google Scholar]
  9. Catterall WA, Goldin AL, Waxman SG, International Union of Pharmacology. XLVII Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacological Reviews. 2005;57:397. doi: 10.1124/pr.57.4.4. [DOI] [PubMed] [Google Scholar]
  10. Cheng Y. Membrane protein structural biology in the era of single particle cryo-EM. Current Opinion in Structural Biology. 2018;52:58–63. doi: 10.1016/j.sbi.2018.08.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Clairfeuille T. Structural basis of α-scorpion toxin action on nav channels. Science. 2019;363:eaav8537. doi: 10.1126/science.aav8573. [DOI] [PubMed] [Google Scholar]
  12. Coleman RA, Johnson M, Nials AT, Vardey CJ. Exosites: their current status, and their relevance to the duration of action of long-acting beta 2-adrenoceptor agonists. Trends in Pharmacological Sciences. 1996;17:324–330. [PubMed] [Google Scholar]
  13. Congreve M, Dias JM, Marshall FH. Structure-Based drug design for G protein-coupled receptors. Progress in Medicinal Chemistry. 2014;53:1–63. doi: 10.1016/B978-0-444-63380-4.00001-9. [DOI] [PubMed] [Google Scholar]
  14. de Lera Ruiz M, Kraus RL. Voltage-Gated sodium channels: structure, function, pharmacology, and clinical indications. Journal of Medicinal Chemistry. 2015;58:7093–7118. doi: 10.1021/jm501981g. [DOI] [PubMed] [Google Scholar]
  15. Dib-Hajj SD, Yang Y, Black JA, Waxman SG. The Na (V) 1.7 sodium channel: from molecule to man. Nature Reviews. Neuroscience. 2013;14:49–62. doi: 10.1038/nrn3404. [DOI] [PubMed] [Google Scholar]
  16. Dickson CJ, Hornak V, Velez-Vega C, McKay DJJ, Reilly J, Sandham DA, Shaw D, Fairhurst RA, Charlton SJ, Sykes DA, Pearlstein RA, Duca JS. Uncoupling the structure-activity relationships of β2 adrenergic receptor ligands from membrane binding. Journal of Medicinal Chemistry. 2016;59:5780–5789. doi: 10.1021/acs.jmedchem.6b00358. [DOI] [PubMed] [Google Scholar]
  17. DiMauro EF, Altmann S, Berry LM, Bregman H, Chakka N, Chu-Moyer M, Bojic EF, Foti RS, Fremeau R, Gao H, Gunaydin H, Guzman-Perez A, Hall BE, Huang H, Jarosh M, Kornecook T, Lee J, Ligutti J, Liu D, Moyer BD, Ortuno D, Rose PE, Schenkel LB, Taborn K, Wang J, Wang Y, Yu V, Weiss MM. Application of a parallel synthetic strategy in the discovery of biaryl acyl sulfonamides as efficient and selective Nav1.7 inhibitors. Journal of Medicinal Chemistry. 2016;59:7818–7839. doi: 10.1021/acs.jmedchem.6b00425. [DOI] [PubMed] [Google Scholar]
  18. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of coot. Acta Crystallographica. Section D, Biological Crystallography. 2010;66:486–501. doi: 10.1107/S0907444910007493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Focken T, Liu S, Chahal N, Dauphinais M, Grimwood ME, Chowdhury S, Hemeon I, Bichler P, Bogucki D, Waldbrook M, Bankar G, Sojo LE, Young C, Lin S, Shuart N, Kwan R, Pang J, Chang JH, Safina BS, Sutherlin DP, Johnson JP, Jr, Dehnhardt CM, Mansour TS, Oballa RM, Cohen CJ, Robinette CL. Discovery of aryl sulfonamides as isoform-selective inhibitors of Nav1.7 with efficacy in rodent pain models. ACS Medicinal Chemistry Letters. 2016;7:277–282. doi: 10.1021/acsmedchemlett.5b00447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Focken T, Chowdhury S, Zenova A, Grimwood ME, Chabot C, Sheng T, Hemeon I, Decker SM, Wilson M, Bichler P, Jia Q, Sun S, Young C, Lin S, Goodchild SJ, Shuart NG, Chang E, Xie Z, Li B, Khakh K, Bankar G, Waldbrook M, Kwan R, Nelkenbrecher K, Karimi Tari P, Chahal N, Sojo L, Robinette CL, White AD, Chen C-A, Zhang Y, Pang J, Chang JH, Hackos DH, Johnson JP, Jr, Cohen CJ, Ortwine DF, Sutherlin DP, Dehnhardt CM, Safina BS. Design of conformationally constrained acyl sulfonamide isosteres: identification of N- ([ 1,2,4 ] triazolo [ 4,3- a ] pyridin-3-yl) methane-sulfonamides as potent and selective hnav1.7 inhibitors for the treatment of pain. Journal of Medicinal Chemistry. 2018;61:4810–4831. doi: 10.1021/acs.jmedchem.7b01826. [DOI] [PubMed] [Google Scholar]
  21. Goddard TD, Huang CC, Meng EC, Pettersen EF, Couch GS, Morris JH, Ferrin TE. UCSF chimerax: meeting modern challenges in visualization and analysis. Protein Science. 2018;27:14–25. doi: 10.1002/pro.3235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Graceffa RF, Boezio AA, Able J, Altmann S, Berry LM, Boezio C, Butler JR, Chu-Moyer M, Cooke M, DiMauro EF, Dineen TA, Feric Bojic E, Foti RS, Fremeau RT, Jr, Guzman-Perez A, Gao H, Gunaydin H, Huang H, Huang L, Ilch C, Jarosh M, Kornecook T, Kreiman CR, La DS, Ligutti J, Milgram BC, Lin M-HJ, Marx IE, Nguyen HN, Peterson EA, Rescourio G, Roberts J, Schenkel L, Shimanovich R, Sparling BA, Stellwagen J, Taborn K, Vaida KR, Wang J, Yeoman J, Yu V, Zhu D, Moyer BD, Weiss MM. Sulfonamides as selective Nav1.7 inhibitors: optimizing potency, pharmacokinetics, and metabolic properties to obtain atropisomeric quinolinone (AM-0466) that affords robust in vivo activity. Journal of Medicinal Chemistry. 2017;60:5990–6017. doi: 10.1021/acs.jmedchem.6b01850. [DOI] [PubMed] [Google Scholar]
  23. Grant T, Rohou A, Grigorieff N. CisTEM, user-friendly software for single-particle image processing. eLife. 2018;7:e35383. doi: 10.7554/eLife.35383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Huang G, Liu D, Wang W, Wu Q, Chen J, Pan X, Shen H, Yan N. High-resolution structures of human nav1.7 reveal gating modulation through α-π helical transition of s6iv. Cell Reports. 2022;39:110735. doi: 10.1016/j.celrep.2022.110735. [DOI] [PubMed] [Google Scholar]
  25. Kotla NK, Kumari KA, Gunda SK, Shaik M. 3D-QSAR and molecular docking studies of acylsulfonamides as nav1.7 inhibitors in chronic pain. Res. J. Life Sci. Bioinform. Pharm. Chem. Sci. 2019;5:120. doi: 10.26479/2019.0503.10. [DOI] [Google Scholar]
  26. Kschonsak M, Chua HC, Weidling C, Chakouri N, Noland CL, Schott K, Chang T, Tam C, Patel N, Arthur CP, Leitner A, Ben-Johny M, Ciferri C, Pless SA, Payandeh J. Structural architecture of the human NALCN channelosome. Nature. 2022;603:180–186. doi: 10.1038/s41586-021-04313-5. [DOI] [PubMed] [Google Scholar]
  27. Li X, Xu F, Xu H, Zhang S, Gao Y, Zhang H, Dong Y, Zheng Y, Yang B, Sun J, Zhang XC, Zhao Y, Jiang D. Structural basis for modulation of human NaV1.3 by clinical drug and selective antagonist. Nature Communications. 2022;13:1286. doi: 10.1038/s41467-022-28808-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Luo G, Chen L, Easton A, Newton A, Bourin C, Shields E, Mosure K, Soars MG, Knox RJ, Matchett M, Pieschl RL, Post-Munson DJ, Wang S, Herrington J, Graef J, Newberry K, Sivarao DV, Senapati A, Bristow LJ, Meanwell NA, Thompson LA, Dzierba C. Discovery of indole- and indazole-acylsulfonamides as potent and selective Nav1.7 inhibitors for the treatment of pain. Journal of Medicinal Chemistry. 2019;62:831–856. doi: 10.1021/acs.jmedchem.8b01550. [DOI] [PubMed] [Google Scholar]
  29. Mason RP, Rhodes DG, Herbette LG. Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. Journal of Medicinal Chemistry. 1991;34:869–877. doi: 10.1021/jm00107a001. [DOI] [PubMed] [Google Scholar]
  30. Mastronarde DN. Automated electron microscope tomography using robust prediction of specimen movements. Journal of Structural Biology. 2005;152:36–51. doi: 10.1016/j.jsb.2005.07.007. [DOI] [PubMed] [Google Scholar]
  31. Masureel M, Zou Y, Picard L-P, van der Westhuizen E, Mahoney JP, Rodrigues JP, Mildorf TJ, Dror RO, Shaw DE, Bouvier M, Pardon E, Steyaert J, Sunahara RK, Weis WI, Zhang C, Kobilka BK. Structural insights into binding specificity, efficacy and bias of a β2AR partial agonist. Nature Chemical Biology. 2018;14:1059–1066. doi: 10.1038/s41589-018-0145-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. McCormack K, Santos S, Chapman ML, Krafte DS, Marron BE, West CW, Krambis MJ, Antonio BM, Zellmer SG, Printzenhoff D, Padilla KM, Lin Z, Wagoner PK, Swain NA, Stupple PA, de Groot M, Butt RP, Castle NA. Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels. PNAS. 2013;110:E2724–E2732. doi: 10.1073/pnas.1220844110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. McDonnell A, Collins S, Ali Z, Iavarone L, Surujbally R, Kirby S, Butt RP. Efficacy of the Nav1.7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy. Pain. 2018;159:1465–1476. doi: 10.1097/j.pain.0000000000001227. [DOI] [PubMed] [Google Scholar]
  34. McKerrall SJ, Sutherlin DP. Nav1.7 inhibitors for the treatment of chronic pain. Bioorganic & Medicinal Chemistry Letters. 2018;28:3141–3149. doi: 10.1016/j.bmcl.2018.08.007. [DOI] [PubMed] [Google Scholar]
  35. McKerrall SJ, Nguyen T, Lai KW, Bergeron P, Deng L, DiPasquale A, Chang JH, Chen J, Chernov-Rogan T, Hackos DH, Maher J, Ortwine DF, Pang J, Payandeh J, Proctor WR, Shields SD, Vogt J, Ji P, Liu W, Ballini E, Schumann L, Tarozzo G, Bankar G, Chowdhury S, Hasan A, Johnson JP, Jr, Khakh K, Lin S, Cohen CJ, Dehnhardt CM, Safina BS, Sutherlin DP. Structure- and ligand-based discovery of chromane arylsulfonamide Nav1.7 inhibitors for the treatment of chronic pain. Journal of Medicinal Chemistry. 2019;62:4091–4109. doi: 10.1021/acs.jmedchem.9b00141. [DOI] [PubMed] [Google Scholar]
  36. Moriarty NW, Grosse-Kunstleve RW, Adams PD. Electronic ligand builder and optimization workbench (elbow): a tool for ligand coordinate and restraint generation. Acta Crystallographica. Section D, Biological Crystallography. 2009;65:1074–1080. doi: 10.1107/S0907444909029436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Noreng S, Li T, Payandeh J. Structural pharmacology of voltage-gated sodium channels. Journal of Molecular Biology. 2021;433:166967. doi: 10.1016/j.jmb.2021.166967. [DOI] [PubMed] [Google Scholar]
  38. Payandeh J, Hackos DH. In: Handbook of Experimental Pharmacology. Payandeh J, editor. Springer; 2018. Selective ligands and drug discovery targeting the voltage-gated sodium channel nav1.7; pp. 271–306. [DOI] [PubMed] [Google Scholar]
  39. Payandeh J, Volgraf M. Ligand binding at the protein-lipid interface: strategic considerations for drug design. Nature Reviews. Drug Discovery. 2021;20:710–722. doi: 10.1038/s41573-021-00240-2. [DOI] [PubMed] [Google Scholar]
  40. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF chimera -- a visualization system for exploratory research and analysis. Journal of Computational Chemistry. 2004;25:1605–1612. doi: 10.1002/jcc.20084. [DOI] [PubMed] [Google Scholar]
  41. Rhodes DG, Newton R, Butler R, Herbette L. Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers. Molecular Pharmacology. 1992;42:596–602. [PubMed] [Google Scholar]
  42. Roecker AJ, Layton ME, Pero JE, Kelly MJ, Greshock TJ, Kraus RL, Li Y, Klein R, Clements M, Daley C, Jovanovska A, Ballard JE, Wang D, Zhao F, Brunskill APJ, Peng X, Wang X, Sun H, Houghton AK, Burgey CS. Discovery of arylsulfonamide nav1.7 inhibitors: IVIVC, MPO methods, and optimization of selectivity profile. ACS Medicinal Chemistry Letters. 2021;12:1038–1049. doi: 10.1021/acsmedchemlett.1c00218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Rohou A, Grigorieff N. CTFFIND4: fast and accurate defocus estimation from electron micrographs. Journal of Structural Biology. 2015;192:216–221. doi: 10.1016/j.jsb.2015.08.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Rothenberg ME, Tagen M, Chang JH, Boyce-Rustay J, Friesenhahn M, Hackos DH, Hains A, Sutherlin D, Ward M, Cho W. Safety, tolerability, and pharmacokinetics of GDC-0276, a novel Nav1.7 inhibitor, in a first-in-human, single- and multiple-dose study in healthy volunteers. Clinical Drug Investigation. 2019;39:873–887. doi: 10.1007/s40261-019-00807-3. [DOI] [PubMed] [Google Scholar]
  45. Rougé L, Chiang N, Steffek M, Kugel C, Croll TI, Tam C, Estevez A, Arthur CP, Koth CM, Ciferri C, Kraft E, Payandeh J, Nakamura G, Koerber JT, Rohou A. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science. 2020;367:1224–1230. doi: 10.1126/science.aaz9356. [DOI] [PubMed] [Google Scholar]
  46. Safina BS, McKerrall SJ, Sun S, Chen CA, Chowdhury S, Jia Q, Li J, Zenova AY, Andrez JC, Bankar G, Bergeron P, Chang JH, Chang E, Chen J, Dean R, Decker SM, DiPasquale A, Focken T, Hemeon I, Khakh K, Kim A, Kwan R, Lindgren A, Lin S, Maher J, Mezeyova J, Misner D, Nelkenbrecher K, Pang J, Reese R, Shields SD, Sojo L, Sheng T, Verschoof H, Waldbrook M, Wilson MS, Xie Z, Young C, Zabka TS, Hackos DH, Ortwine DF, White AD, Johnson JP, Robinette CL, Dehnhardt CM, Cohen CJ, Sutherlin DP. Discovery of acyl-sulfonamide nav1.7 inhibitors GDC-0276 and GDC-0310. Journal of Medicinal Chemistry. 2021;64:2953–2966. doi: 10.1021/acs.jmedchem.1c00049. [DOI] [PubMed] [Google Scholar]
  47. Scheres SHW. RELION: implementation of a Bayesian approach to cryo-EM structure determination. Journal of Structural Biology. 2012;180:519–530. doi: 10.1016/j.jsb.2012.09.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Shen H, Zhou Q, Pan X, Li Z, Wu J, Yan N. Structure of a eukaryotic voltage-gated sodium channel at near-atomic resolution. Science. 2017;355:eaal4326. doi: 10.1126/science.aal4326. [DOI] [PubMed] [Google Scholar]
  49. Shen H, Li Z, Jiang Y, Pan X, Wu J, Cristofori-Armstrong B, Smith JJ, Chin YKY, Lei J, Zhou Q, King GF, Yan N. Structural basis for the modulation of voltage-gated sodium channels by animal toxins. Science. 2018;362:eaau2596. doi: 10.1126/science.aau2596. [DOI] [PubMed] [Google Scholar]
  50. Shen H., Liu D, Wu K, Lei J, Yan N. Structures of human Nav1.7 channel in complex with auxiliary subunits and animal toxins. Science. 2019;363:1303–1308. doi: 10.1126/science.aaw2493. [DOI] [PubMed] [Google Scholar]
  51. Siebenga P, van Amerongen G, Hay JL, McDonnell A, Gorman D, Butt R, Groeneveld GJ. Lack of detection of the analgesic properties of PF-05089771, a selective NaV 1.7 inhibitor, using a battery of pain models in healthy subjects. Clinical and Translational Science. 2020;13:318–324. doi: 10.1111/cts.12712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Sun S, Jia Q, Zenova AY, Wilson MS, Chowdhury S, Focken T, Li J, Decker S, Grimwood ME, Andrez J-C, Hemeon I, Sheng T, Chen C-A, White A, Hackos DH, Deng L, Bankar G, Khakh K, Chang E, Kwan R, Lin S, Nelkenbrecher K, Sellers BD, DiPasquale AG, Chang J, Pang J, Sojo L, Lindgren A, Waldbrook M, Xie Z, Young C, Johnson JP, Robinette CL, Cohen CJ, Safina BS, Sutherlin DP, Ortwine DF, Dehnhardt CM. Identification of selective acyl sulfonamide-cycloalkylether inhibitors of the voltage-gated sodium channel (NaV) 1.7 with potent analgesic activity. Journal of Medicinal Chemistry. 2019;62:908–927. doi: 10.1021/acs.jmedchem.8b01621. [DOI] [PubMed] [Google Scholar]
  53. Sutherlin D, inventor. Therapeutic compounds and methods of use thereof. US11028075B2. WIPO. 2021 https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020009946
  54. Swain NA, Batchelor D, Beaudoin S, Bechle BM, Bradley PA, Brown AD, Brown B, Butcher KJ, Butt RP, Chapman ML, Denton S, Ellis D, Galan SRG, Gaulier SM, Greener BS, de Groot MJ, Glossop MS, Gurrell IK, Hannam J, Johnson MS, Lin Z, Markworth CJ, Marron BE, Millan DS, Nakagawa S, Pike A, Printzenhoff D, Rawson DJ, Ransley SJ, Reister SM, Sasaki K, Storer RI, Stupple PA, West CW. Discovery of clinical candidate 4- [ 2- (5-amino-1H-pyrazol-4-yl) -4-chlorophenoxy ] -5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): design and optimization of diaryl ether aryl sulfonamides as selective inhibitors of Nav1.7. Journal of Medicinal Chemistry. 2017;60:7029–7042. doi: 10.1021/acs.jmedchem.7b00598. [DOI] [PubMed] [Google Scholar]
  55. Sykes DA, Parry C, Reilly J, Wright P, Fairhurst RA, Charlton SJ. Observed drug-receptor association rates are governed by membrane affinity: the importance of establishing `` micro-pharmacokinetic/pharmacodynamic relationships'' at the β2-adrenoceptor. Molecular Pharmacology. 2014;85:608–617. doi: 10.1124/mol.113.090209. [DOI] [PubMed] [Google Scholar]
  56. Terwilliger TC, Ludtke SJ, Read RJ, Adams PD, Afonine PV. Improvement of cryo-EM maps by density modification. Nature Methods. 2020;17:923–927. doi: 10.1038/s41592-020-0914-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Weiss MM, Dineen TA, Marx IE, Altmann S, Boezio A, Bregman H, Chu-Moyer M, DiMauro EF, Feric Bojic E, Foti RS, Gao H, Graceffa R, Gunaydin H, Guzman-Perez A, Huang H, Huang L, Jarosh M, Kornecook T, Kreiman CR, Ligutti J, La DS, Lin M-HJ, Liu D, Moyer BD, Nguyen HN, Peterson EA, Rose PE, Taborn K, Youngblood BD, Yu V, Fremeau RT., Jr Sulfonamides as selective Nav1.7 inhibitors: optimizing potency and pharmacokinetics while mitigating metabolic liabilities. Journal of Medicinal Chemistry. 2017;60:5969–5989. doi: 10.1021/acs.jmedchem.6b01851. [DOI] [PubMed] [Google Scholar]
  58. Williams CJ, Headd JJ, Moriarty NW, Prisant MG, Videau LL, Deis LN, Verma V, Keedy DA, Hintze BJ, Chen VB, Jain S, Lewis SM, Arendall WB, Snoeyink J, Adams PD, Lovell SC, Richardson JS, Richardson DC. MolProbity: more and better reference data for improved all-atom structure validation. Protein Science. 2018;27:293–315. doi: 10.1002/pro.3330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Wu Y-J, Guernon J, Shi J, Ditta J, Robbins KJ, Rajamani R, Easton A, Newton A, Bourin C, Mosure K, Soars MG, Knox RJ, Matchett M, Pieschl RL, Post-Munson DJ, Wang S, Herrington J, Graef J, Newberry K, Bristow LJ, Meanwell NA, Olson R, Thompson LA, Dzierba C. Development of new benzenesulfonamides as potent and selective Nav1.7 inhibitors for the treatment of pain. Journal of Medicinal Chemistry. 2017;60:2513–2525. doi: 10.1021/acs.jmedchem.6b01918. [DOI] [PubMed] [Google Scholar]
  60. Xu H, Li T, Rohou A, Arthur CP, Tzakoniati F, Wong E, Estevez A, Kugel C, Franke Y, Chen J, Ciferri C, Hackos DH, Koth CM, Payandeh J. Structural basis of Nav1.7 inhibition by a gating-modifier spider toxin. Cell. 2019;176:1238–1239. doi: 10.1016/j.cell.2019.01.047. [DOI] [PubMed] [Google Scholar]
  61. Zhao Z, Wu H, Wang L, Liu Y, Knapp S, Liu Q, Gray NS. Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery? ACS Chemical Biology. 2014;9:1230–1241. doi: 10.1021/cb500129t. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Zheng SQ, Palovcak E, Armache J-P, Verba KA, Cheng Y, Agard DA. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nature Methods. 2017;14:331–332. doi: 10.1038/nmeth.4193. [DOI] [PMC free article] [PubMed] [Google Scholar]

Editor's evaluation

Jon T Sack 1

This fundamental study describes the structure-based design of novel hybrid inhibitors targeting a human sodium channel which is a pain target. Exceptionally strong evidence for key claims was produced with a structural biological pipeline for iterative structural determination of drugs complexed with an engineered sodium channel. This work is expected to be of interest to biophysicists, drug developers, neurobiologists and pain researchers.

Decision letter

Editor: Jon T Sack1
Reviewed by: Vladimir Yarov-Yarovoy2, Michael A Cianfrocco3, Hiro Furukawa4

Our editorial process produces two outputs: (i) public reviews designed to be posted alongside the preprint for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.

Decision letter after peer review:

Thank you for submitting your article "CryoEM reveals unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors" for consideration by eLife. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Richard Aldrich as the Senior Editor. The following individuals involved in the review of your submission have agreed to reveal their identity: Vladimir Yarov-Yarovoy (Reviewer #1); Michael A Cianfrocco (Reviewer #2); Hiro Furukawa (Reviewer #3).

The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.

Essential revisions:

1) Please show electrophysiological data along with statistical analyses.

2) Clarify what the advances of the structural biological pipeline are. Based on the description of the pipeline given, reviewers felt the advance was in protein engineering, rather than the implementation of cryo-EM.

3) Address each reviewer's suggestions with changes to the manuscript or explain why manuscript changes are not warranted in rebuttal.

Reviewer #1 (Recommendations for the authors):

1. Add main text and Supplementary figures showing Syncropatch electrophysiology potency data for all compounds presented in the manuscript.

2. Include electrophysiology selectivity data for human Nav1.7 versus other human Nav channels for at least one of the novel hybrid inhibitors. These data will be useful to compare the selectivity profiles of the novel hybrid inhibitors to the selectivity profiles of arylsulfonamides and acylsulfonamides.

3. Discussion of Nav channel subtype selectivity determinants highlighting residues Y1537 and W1538 would benefit from corresponding multiple sequence alignment of Nav channels in a Supplementary Figure.

4. Add supplementary figures showing hybrid compounds 4 and 5 in complex with VSD4 NaV1.7-NaVPas channel using a layout similar to main text Figures 2 and 3.

5. Clarify in the main text and figure legends that compound 2 is GNE-9296.

6. Clarify in the main text and figure legends that compound 4 is GNE-1305.

7. Explain why DC1a peptide toxin was specifically used to obtain the cryoEM structure of compound 2 in complex with VSD4 NaV1.7-NaVPas channel.

8. Update Supplementary Figure 4 to reflect the Supplementary Figure 4 legend.

9. Add Supplementary Figure 5 to reflect the Supplementary Figure 5 legend.

10. Main text line 205 – add "s" to "suggest" to read "our structure suggests".

Reviewer #2 (Recommendations for the authors):

– One source of weakness can be identified in lines 43-45, where the authors emphasize an established iterative system of structure determination, which has been instrumental to their success in drug development. As such, if the authors want to play up their pipeline, they should elaborate on details of the pipeline: how long did it take for each step, how are class averages selected, how long does it take to go from cryo-EM data collection to final reconstruction and atomic model? At the moment, it is difficult to tell how innovative the pipeline is compared to conventional cryo-EM structure determination. Otherwise, if the authors do not want to expound on this, they can omit their comments on a pipeline.

– The density-modified reconstructions show sharp edges that are non-physiological. The authors need to remedy this to show density that reflects protein structure (i.e., smooth). One approach would include creating composite maps with appropriate local resolutions and B-factors to prevent over-sharpening artifacts.

– Missing legend for Figure 1F-G.

– There are two Supplementary Figure 1 figures. This makes the supplementary figure legend numbering incorrect.

eLife. 2023 Mar 28;12:e84151. doi: 10.7554/eLife.84151.sa2

Author response

Reviewer #1 (Recommendations for the authors):

1. Add main text and Supplementary figures showing Syncropatch electrophysiology potency data for all compounds presented in the manuscript.

Electrophysiology data for all compounds has been added in Figure4—figure supplement 1.

2. Include electrophysiology selectivity data for human Nav1.7 versus other human Nav channels for at least one of the novel hybrid inhibitors. These data will be useful to compare the selectivity profiles of the novel hybrid inhibitors to the selectivity profiles of arylsulfonamides and acylsulfonamides.

We agree with this reviewer that subtype selectivity is an important characteristic of NaV channel inhibitors. We have included selectivity data for various molecules against NaV1.5 and NaV1.6 in Supplementary File 1B. This table is also accompanied by a brief discussion. In addition, the following line has been added to the discussion in the main text:

“Although selectivity was not a key endpoint of the proof-of-concept studies described here, hybrid molecules 2-5 are selective for NaV1.7 over cardiac channel NaV1.5. Further discussion of selectivity patterns in the hybrid series is included in the Supplementary Information (Supplementary File 1B).”

3. Discussion of Nav channel subtype selectivity determinants highlighting residues Y1537 and W1538 would benefit from corresponding multiple sequence alignment of Nav channels in a Supplementary Figure.

We thank the reviewer for this suggestion and we have now added a VSD4 sequence alignment to Figure4—figure supplement 3. We also added further discussion of selectivity pattern in the hybrid series in Supplementary File 1B.

4. Add supplementary figures showing hybrid compounds 4 and 5 in complex with VSD4 NaV1.7-NaVPas channel using a layout similar to main text Figures 2 and 3.

We do present the structure of compound 4 (G-1305) in Figure 4G-I. We did not solve the structure of compound 5 because of its lower potency. We believe that adding the structure of Nav bound to 5 would not add significantly to this manuscript.

5. Clarify in the main text and figure legends that compound 2 is GNE-9296.

We have changed this throughout the text and figures. GNE-9296 is added as an alias for compound 2.

6. Clarify in the main text and figure legends that compound 4 is GNE-1305.

We have changed this throughout the text and figures. GNE-1305 is added as an alia of compound 4.

7. Explain why DC1a peptide toxin was specifically used to obtain the cryoEM structure of compound 2 in complex with VSD4 NaV1.7-NaVPas channel.

We have worked on optimizing the Nav sample during the last several years, exploring different constructs and purification protocols. Originally, we were performing cryoEM structure determination on samples purified in detergent and further stabilized with DC1a. We later moved to nanodisc (in the absence of DC1a) because most of the compound bound samples, purified in nanodisc, refined to better resolution. GNE-9296 represented an exception to this general trend and the structure of Nav bound to this compound, when purified in detegerents in the presence of DC1a, went to the highest resolution. This is the reason why we decided to include this specific structure in the manuscript.

8. Update Supplementary Figure 4 to reflect the Supplementary Figure 4 legend.

We apologize for this mismatch; this is now fixed.

9. Add Supplementary Figure 5 to reflect the Supplementary Figure 5 legend.

We apologize for this mismatch; this is now fixed.

10. Main text line 205 – add "s" to "suggest" to read "our structure suggests".

We apologize for this typo; this is now fixed.

Reviewer #2 (Recommendations for the authors):

– One source of weakness can be identified in lines 43-45, where the authors emphasize an established iterative system of structure determination, which has been instrumental to their success in drug development. As such, if the authors want to play up their pipeline, they should elaborate on details of the pipeline: how long did it take for each step, how are class averages selected, how long does it take to go from cryo-EM data collection to final reconstruction and atomic model? At the moment, it is difficult to tell how innovative the pipeline is compared to conventional cryo-EM structure determination. Otherwise, if the authors do not want to expound on this, they can omit their comments on a pipeline.

We thank this Reviewer for bringing up this specific point. We were interested in performing Structural Based Drug Design (SBDD) on this channel for the last 10 years, initially through X-ray crystallography and then, starting in 2017, by cryoEM. In order to perform real time SBDD, it is imperative that the cycle of structure determination matches the cycle of design and synthesis of novel compounds. Initially, the time comprising protein purification, grid preparation, data collection and structure determination was approximately 1.5 months/compound. We worked on every single step to diminish this timeline and bring this to 2 weeks. This included having a more robust sample (the optimum was by utilizing nanodiscs), optimize grid freezing and data collection (to maximize number of particles and orientation for structure determination), and finally streamline data processing (based on our improved experience with this sample). We do realize that in the meantime the cryoEM field has significantly improved making these optimizations very common for challenging samples. That said, reported small molecule cryoEM structures are generally retrospective, including the ones showcasing cutting edge technology (i.e. Terrett et al., 2021). This manuscript represents, to our knowledge, one of the very first examples of real-time SBDD and utilization of cryoEM to design a new class of compounds with improved properties and potential for clinical studies. We have changed the text to:

“To advance inhibitor design targeting the NaV1.7 channel, we established an iterative system to routinely obtain high-resolution ligand-bound NaV1.7 structures using cryogenic electron microscopy (cryo-EM).”

Citation:

Tetrahydrofuran-Based Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists: Ligand-Based Discovery, Activity in a Rodent Asthma Model, and Mechanism-of-Action via Cryogenic Electron Microscopy.

Terrett JA, Chen H, Shore DG, Villemure E, Larouche-Gauthier R, Déry M, Beaumier F, Constantineau-Forget L, Grand-Maître C, Lépissier L, Ciblat S, Sturino C, Chen Y, Hu B, Lu A, Wang Y, Cridland AP, Ward SI, Hackos DH, Reese RM, Shields SD, Chen J, Balestrini A, Riol-Blanco L, Lee WP, Liu J, Suto E, Wu X, Zhang J, Ly JQ, La H, Johnson K, Baumgardner M, Chou KJ, Rohou A, Rougé L, Safina BS, Magnuson S, Volgraf M. J Med Chem. 2021 Apr 8;64(7):3843-3869.

– The density-modified reconstructions show sharp edges that are non-physiological. The authors need to remedy this to show density that reflects protein structure (i.e., smooth). One approach would include creating composite maps with appropriate local resolutions and B-factors to prevent over-sharpening artifacts.

We thank the reviewer for this suggestion. We have also deposited the half-maps and non-modified full maps that show the smooth nature of the protein.

– Missing legend for Figure 1F-G.

We thank the reviewer for pointing out this error. We have now corrected the Figure and the Figure legend information.

– There are two Supplementary Figure 1 figures. This makes the supplementary figure legend numbering incorrect.

We thank the reviewer for pointing out this error. We have corrected the numbering of the Supplementary Figure legends.

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Data Citations

    1. Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Otwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeth J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the arylsulfonamide inhibitor GNE-3565. RCSB Protein Data Bank. 8F0R
    2. Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Otwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the arylsulfonamide inhibitor GNE-3565. Electron Microscopy Data Bank. EMD-28778
    3. Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Ortwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the acylsulfonamide inhibitor GDC-0310. RCSB Protein Data Bank. 8F0Q
    4. Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Ortwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the acylsulfonamide inhibitor GDC-0310. Electron Microscopy Data Bank. EMD-28777
    5. Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Ortwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the hybrid inhibitor GNE-9296. RCSB Protein Data Bank. 8F0S
    6. Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Ortwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the hybrid inhibitor GNE-9296. Electron Microscopy Data Bank. EMD-28779
    7. Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Ortwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the hybrid inhibitor GNE-1305. RCSB Protein Data Bank. 8F0P
    8. Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Ortwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the hybrid inhibitor GNE-1305. Electron Microscopy Data Bank. EMD-28776

    Supplementary Materials

    Figure 1—figure supplement 1—source data 1. Source data of VSD4-NaV1.7-NaVPas purification.
    elife-84151-fig1-figsupp1-data1.zip (606.5KB, zip)
    Supplementary file 1. Experimental details for Cryo-EM, compound synthesis and characterization, and NaV subtype selectivity for selected NaV1.7 inhibitors.

    (A) Cryogenic electron microscopy (cryo-EM) data collection, refinement and validation statistics. (B) NaV subtype selectivity for selected hybrid compounds.

    elife-84151-supp1.docx (872.5KB, docx)
    MDAR checklist
    elife-84151-mdarchecklist1.docx (99.9KB, docx)

    Data Availability Statement

    All data generated or analyzed during this study are included in the manuscript and supporting files. The NaV1.7-NaVPas/GNE-3565 coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0R and EMDB entry ID EMD-28778, respectively. The NaV1.7-NaVPas/GDC-0310 coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0Q and EMDB entry ID EMD-28777, respectively. The NaV1.7-NaVPas bound to the hybrid molecule 2 (GNE-9296) coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0S and EMDB entry ID EMD-28779, respectively. The NaV1.7-NaVPas bound to the hybrid molecule 4 (GNE-1305) coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0P and EMDB entry ID EMD-28776, respectively.

    The following datasets were generated:

    Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Otwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeth J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the arylsulfonamide inhibitor GNE-3565. RCSB Protein Data Bank. 8F0R

    Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Otwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the arylsulfonamide inhibitor GNE-3565. Electron Microscopy Data Bank. EMD-28778

    Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Ortwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the acylsulfonamide inhibitor GDC-0310. RCSB Protein Data Bank. 8F0Q

    Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Ortwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the acylsulfonamide inhibitor GDC-0310. Electron Microscopy Data Bank. EMD-28777

    Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Ortwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the hybrid inhibitor GNE-9296. RCSB Protein Data Bank. 8F0S

    Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Ortwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the hybrid inhibitor GNE-9296. Electron Microscopy Data Bank. EMD-28779

    Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Ortwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the hybrid inhibitor GNE-1305. RCSB Protein Data Bank. 8F0P

    Kschonsak M, Jao CC, Arthur CP, Rohou AL, Bergeron P, Ortwine D, McKerall SJ, Hackos DH, Deng L, Chen J, Sutherlin D, Dragovich PS, Volgraf M, Wright MR, Payandeh J, Ciferri C, Tellis JC. 2023. Structure of VSD4-NaV1.7-NaVPas channel chimera bound to the hybrid inhibitor GNE-1305. Electron Microscopy Data Bank. EMD-28776

    Articles from eLife are provided here courtesy of eLife Sciences Publications, Ltd

    RESOURCES